Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera)
Reference Number: CP.PHAR.238
Effective Date: 07.01.16
Last Review Date: 05.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Methoxy polyethylene glycol-epoetin beta (Mircera®) is an erythropoiesis-stimulating agent (ESA).

FDA Approved Indication(s)
Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:
• Adult patients on dialysis and patients not on dialysis
• Pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA

Limitation(s) of use:
• Mircera is not indicated and is not recommended for use:
  o In the treatment of anemia due to cancer chemotherapy
  o As a substitute for red blood cell (RBC) transfusions in patients who require immediate correction of anemia.
• Mircera has not been shown to improve symptoms, physical functioning or health-related quality of life.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Mircera is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Anemia of Chronic Kidney Disease (must meet all):
      1. Diagnosis of anemia of CKD, and member meets one of the following (a or b):
         a. Age ≥ 18 years (dialysis status is irrelevant);
         b. Age ≥ 5 years to ≤ 17 years, on hemodialysis, and will be converting from another ESA agent (e.g., epoetin alfa, darbepoetin alfa)
      2. Prescribed by or in consultation with a hematologist or nephrologist;
      3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
      4. Pretreatment hemoglobin < 10 g/dL;
5. Failure of Retacrit® unless contraindicated or clinically significant adverse effects are experienced;
6. Dosing interval does not exceed one of the following (a or b):
   a. Adults: SC or IV once every two weeks;
   b. Pediatrics: IV once every four weeks.

**Approval duration:**
- Medicaid/HIM – 6 months
- Commercial – 6 months or to member’s renewal period, whichever is longer

**B. Other diagnoses/indications**
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Anemia of Chronic Kidney Disease** (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Failure of Retacrit® unless contraindicated or clinically significant adverse effects are experienced;
4. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
5. Dosing interval does not exceed one of the following (a or b):
   a. Adults: SC or IV once every two weeks;
   b. Pediatrics: IV once every four weeks.

**Approval duration:**
- Medicaid/HIM – 6 months
- Commercial – 6 months or to member’s renewal period, whichever is longer

**B. Other diagnoses/indications** (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   **Approval duration:** Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

**A.** Anemia due to cancer chemotherapy;

**B.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.
IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

- CKD: chronic kidney disease
- ESA: erythropoiesis-stimulating agent
- FDA: Food and Drug Administration
- RBC: red blood cell

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| Retacrit® (epoetin alfa-epbx) | Anemia due to CKD  
Initial dose: 50 to 100 Units/kg 3 times weekly (adults) IV or SC and 50 Units/kg 3 times weekly (pediatric patients ages 1 month or older) IV or SC. Individualize maintenance dose. IV route recommended for patients on hemodialysis | Varies depending on indication, frequency of administration, and individual response |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Uncontrolled hypertension
  - Pure red cell aplasia (PRCA) that begins after treatment with erythropoietin protein drugs
  - Allergic reactions, anaphylaxis
- Boxed warning(s): ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence

Appendix D: General Information

- The 2012 Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease state that there is no evidence that any given ESA brand is superior to another in terms of patient outcomes. It is considered opinion of the Work Group that the likelihood of differences in clinical outcomes among ESA brands is low. The guideline recommends choosing an ESA based on the balance of pharmacodynamics, safety information, clinical outcome data, costs, and availability (Level 1, Grade D recommendation).

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| Anemia due to CKD   | Adult patients with CKD on or not on dialysis  
Initial treatment: 0.6 mcg/kg body weight SC or IV once every two weeks | Varies       |
### Indication | Dosing Regimen | Maximum Dose
--- | --- | ---
Maintenance treatment: dose twice that of the every-two-week dose SC or IV once monthly |  
Conversion from another ESA: dosed SC or IV once monthly or once every two weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion |  
Pediatric patients with CKD on hemodialysis | Conversion from another ESA: dosed IV once every four weeks based on total weekly epoetin alfa or darbepoetin alfa dose at time of conversion. |

### VI. Product Availability
Injection (single-dose prefilled syringe): 30, 50, 75, 100, 120, 150, 200, or 250 mcg in 0.3 mL solution; 360 mcg in 0.6 mL solution

### VII. References

### Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0887</td>
<td>Injection, epoetin beta, 1 microgram, (for ESRD on dialysis)</td>
</tr>
<tr>
<td>J0888</td>
<td>Injection, epoetin beta, 1 microgram, (for Non ESRD use)</td>
</tr>
</tbody>
</table>

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed.</td>
<td>05.16</td>
</tr>
<tr>
<td>Removed requirement related to failure of, or contraindication or intolerance to Epogen.</td>
<td>09.16</td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial: added prescriber specialty; modified requirement related to adequate iron stores by requiring current (within the last 3 months) serum ferritin or serum transferrin saturation lab values; added dosing interval does not exceed once every 2 weeks per PI (and on re-auth); re-auth: modified requirement related to hemoglobin level to allow reduction in dose per PI; updated references.</td>
<td>05.17</td>
<td>06.17</td>
</tr>
<tr>
<td>2Q 2018 annual review: policies combined for Medicaid and HIM line of business; removed subjective criteria since specialist requirement is present; changed approval duration from 12 weeks to 6 months; references reviewed and updated.</td>
<td>01.12.18</td>
<td>05.18</td>
</tr>
<tr>
<td>No significant changes: age extension for a current P &amp; T approved use (criteria added to allow treatment of anemia in pediatric patients with CKD age 5 to 17 years of age on hemodialysis who are converting from another ESA per labeling changes); added new 360 mcg/0.6 mL dosage strength.</td>
<td>07.16.18</td>
<td></td>
</tr>
<tr>
<td>2Q 2019 annual review: No significant changes; references reviewed and updated.</td>
<td>01.30.19</td>
<td>05.19</td>
</tr>
<tr>
<td>2Q 2020 annual review: added Commercial line of business (retired CP.CPA.322); added redirection to biosimilar ESA Retacrit per existing clinical guidance; Section IA,1b clarified Age ≥ 5 years to ≤ 17 years; references reviewed and updated.</td>
<td>02.13.20</td>
<td>05.20</td>
</tr>
<tr>
<td>Added Appendix D and reference to KDIGO guidelines that do not indicate preference for any ESA.</td>
<td>06.30.20</td>
<td></td>
</tr>
<tr>
<td>Added to Section II for continued therapy redirection to Retacrit.</td>
<td>08.18.20</td>
<td></td>
</tr>
</tbody>
</table>

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,
contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.